Lupin Limited · NSE:LUPIN
Lupin — Q2 FY2022 Earnings Presentation
13 slides from Lupin's earnings presentation, Oct 28, 2021
Slide 1: Exchange cover letter for Q2 FY2022 Investor Presentation
October 28, 2021 BSE Limited Department of Corporate Services, P. J. Towers, Dalal Street, MUMBAI - 400 001. National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. Dear Sir/Madam, Sub: Q2 FY2022 Investor Presentation. Pursuant to Regulation 3
Slide 2: Investor Presentation Q2 FY2022
Investor Presentation Q2 FY2022 October 28, 2021
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ
Slide 4: Lupin – Awards and Accolades
Lupin – Awards and Accolades • Vinita Gupta named among Most Powerful Women in Business in India – #7 by Fortune India • India Pharma Leader Award - India Pharma 2020 and India Medical Device 2020 conference organized by FICCI and the Ministry of Chemicals and Fertilizers, GOI • Lupin ranked No.1 in
Slide 5: Q2 FY2022 Snapshot
Q2 FY2022 Snapshot Important developments Sales (INR mn, YoY Growth) Commercial North America, Mr. Nilesh.D.Gupta India, • Sequential uptake in US generics business driven by Managing Director 15,435, 16% 14,291, 2% Lupin Limited ramp up in Albuterol and Brovana AG^ • India business continues to be
Slide 6: Manufacturing and R&D – Diverse Global Network
Manufacturing and R&D – Diverse Global Network Global Commercial Presence 100 23 7 Countries where Countries with Countries with OPERATIONS products are sold marketing offices subsidiaries RESEARCH 15 7 R&D Sites Manufacturing Sites ◼ 12 USFDA inspected sites ◼ 444 US ANDAs; 292 approved ◼ 30 bn+ ex
Slide 7: Financial Results Review
Financial Results Review
Slide 8: P&L Highlights - Q2 FY 2022
P&L Highlights- Q2 FY 2022 Q2 % of Q1 % of QoQ Q2 % of YoY Amount in INR mn FY22 sales FY22 sales growth FY21 sales growth Sales 40,034 100.0% 42,374 100.0% - 5.5%* 37,818 100.0% 5.9% Other operating income 879 2.2% 328 0.8% 168.0% 532 1.4% 65.2% Total Revenue from operations 40,913 102.2% 42,702 10
Slide 9: North America
Q2FY22 YoY QoQ North America 36% 2.2% 7.2% Gaining momentum Consolidating our position in the US1 US quarterly sales ($ mn) #3 #3 #3 #3 #3 195 #4 188 184 140 4.5 180 120 4 172 100 129 123 121 120 3.5 80 109 3 2.5 60 83 2 65 63 1.5 40 51 53 55 20 45 1 0.5 0 0 2016-17 2017-18 2018-19 2019-20 2020-21 Q
Slide 10: India
Q2FY22 YoY QoQ India 39% % 15.9% 5.7% India business continues to be robust Consistently outpacing chronic market growth India quarterly Sales (INR bn) 5 Year CAGR % Lupin Rank1 MAT MAT 16.4 15.4 Therapy Market Lupin 13.3 13.7 Sep-16 Sep-21 12.9 Acute 9% 5% 13 15 Chronic 12% 15% 5 4 Cardiac 11% 12%
Slide 11: Growth markets
Other Markets • Germany: EUR 8 mn sales in Q2 FY22 EU5 • UK: Launched Luforbec® 100/6 µg pMDI, first branded generic alternative to EMEA Fostair®, indicated for treatment of Asthma & COPD. • Market leader in CVS space South Africa • ZAR 357 mn sales in Q2 FY22 (grew 17% YoY) • 4th largest generics
Slide 12: Key Financial Metrics
Key Financial Metrics R&D (INR mn) Capex (INR mn) 3,843 3,737 1,905 3,479 3,427 3,300 1,396 1,451 1,182 1,057 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q2FY22 R&D (% of Sales) Net debt/ Equity 0.13 10.2% 8.9% 9.1% 8.8% 0.10 8.2% 0.05 (0.02) (0.01) Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q2F
Slide 13: Thank You
THANK YOU Registered Office Lupin Limited, 3rd Floor, Kalpataru Inspire, Off. Western Expressway Highway, Santacruz (East), Mumbai 400 055, India. Phone: +91 22 6640 2323 | Fax: +91 22 6640 2051 | www.lupin.com lupin LupinGlobal LupinWorld Lupin Global